Vivos Therapeutics, Inc. (VVOS) · Oct 19, 2026 · Acquisition

Vivos acquisition closes, but SOD test revenue remains unproven

$12M acquisition — 11% of SOD plus 50% of the test for $12M in preferred stock

Vivos completed its SOD acquisition with no cash paid, adding a potential diagnostic growth channel—but dilution, validation and execution risks remain.

Vivos is in the middle of a business-model pivot: away from relying mainly on dentist enrollment and toward sleep-center alliances, acquired clinical operations and broader OSA testing and treatment services. Recent disclosures also show a sharp cost-reduction effort and continued pressure to restore Nasdaq equity compliance.

The transaction is now closed, but it is primarily an option on a new business line. Vivos received an 11% fully diluted stake in SOD and a 50% co-ownership interest in its pseudohypoxia early-warning test in exchange for preferred stock, with no cash leaving the company.

ItemFiling figure / term
SOD equity acquired11% fully diluted
Test IP acquired50% co-ownership
Consideration$12 million stated value of Series C Preferred
Cash paidNone
Potential conversion at $0.15Up to 80 million common shares, subject to caps
Pro forma stockholders’ equityApproximately $6.6 million
Nasdaq minimum requirement$2.5 million

The upside is still several steps away from revenue. Management points to access to more than 325,000 AHA patients across roughly 3,000 facilities and a potentially multi-million-dollar testing opportunity beginning in 2027, but those channels require new definitive agreements, clinical validation, regulatory progress and bankruptcy-court approval. The filing expressly says the release does not establish that the test predicts any condition. 〔0〕

The deal improves the listing-capital story, but not yet conclusively. Vivos estimates pro forma stockholders’ equity of about $6.6 million and expects the transaction to add more than $10 million, versus Nasdaq’s $2.5 million threshold. However, the accounting treatment still requires review by the auditor and Nasdaq, and compliance must be demonstrated again in a future periodic report.

The consideration creates a meaningful dilution overhang. The Series C Preferred converts at $0.15 per share and could convert into as many as 80 million common shares, although the 19.99% exchange cap applies until stockholder approval and a separate beneficial-ownership limit restricts individual conversions.

The closing is partly known rather than a fresh strategic surprise. The agreement was announced on October 14, 2026 and publicly described before this filing; the new information is that the transaction completed, the exact assignment and co-ownership mechanics are documented, and the potential Nasdaq-equity benefit is now reflected in updated pro forma information. The transaction therefore advances Vivos’s diversification plan, but its commercial value remains contingent rather than demonstrated.

Bottom line: This closes a strategically important expansion beyond sleep-apnea treatment and may help Vivos clear its equity hurdle, but it is not yet a proven revenue event. The immediate trade-off is optionality and balance-sheet support in exchange for execution risk and substantial potential dilution.

What to watch next

AHA agreements and bankruptcy-court approval

Original filing on SEC EDGAR

More Vivos Therapeutics, Inc. news

Vivos acquisition closes, but SOD test revenue remains unproven | VVOS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.